Le Lézard
Classified in: Health, Science and technology, Business
Subject: FINANCING AGREEMENTS

Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding


VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to announce that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Council of Canada in collaboration with the Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research.

Derm-Biome has developed novel compounds with wide ranging pharmacological activities. The grant, which spans 3 years and totals $450,000, will support Derm-Biome's preclinical research activities, with a focus on inflammatory diseases and healthy aging.

Frédéric Couture, Principal Investigator and Head of Pharmaceutical Sciences at TransBIOtech: "This is very exciting news. We are happy to pursue this collaboration with Derm-Biome and help them propel their pipeline closer to new treatments. I believe that, along with co-PIs Dr Sarah Paris-Robidas and Dr Carole-Ann Huppé, our expertise in preclinical pharmacology in synergy with Derm-Biome's scientific team will accelerate future efficacy validation of their products and provide them with the key demonstrations needed for upcoming clinical trial applications."

Derm-Biome CEO Gordon Eberwein: "We are very pleased to have been awarded this Applied Research and Development grant and very much look forward to our continued working relationship with TransBIOtech in helping advance our exciting preclinical pipeline."

About Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to improving skin health and healthy aging. We are developing novel topical therapies for inflammatory skin diseases and precancerous skin conditions/non-melanoma skin cancers that are both highly effective and well tolerated by skin.

Contact
Investor Inquiries:
Gordon Eberwein
[email protected]
https://derm-biomepharmaceuticals.com/



These press releases may also interest you

at 21:00
Full Sail University Kicks Off 14th Annual Hall of Fame Week with "Hall of Game" Esports Event
Full Sail University's Annual Hall of Fame week kicked off with "Hall of Game." This esports event welcomed students and alumni to compete in popular titles including Call of Duty, Rocket League, and Super Smash Bros. Through Full Sail's partnership...

at 21:00
TIER IV to launch robotaxi business in Tokyo, November 2024: Starting with limited operational domains
TIER IV, a pioneer in developing open-source software for autonomous driving (AD) systems, is set to launch a unique robotaxi service in November 2024. Initially targeting areas and times that conventional taxi operators struggle to serve, the...

at 20:14
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 20:00
SUNRATE joins Mastercard's Priceless Planet Coalition
SUNRATE, an intelligent global payment and treasury management platform today announced it has joined Mastercard Priceless Planet Coalition in support of fighting climate change through funding the restoration of 100 million trees. This announcement...

at 20:00
E&R Engineering Corp. Unveils Cutting-Edge Solutions at Semicon SEA 2024 in Kuala Lumpur
The advanced laser and plasma solution provider from Taiwan, E&R Engineering Corp., is confirmed to attend the feast in Semiconductor industry, Semicon SEA 2024, held in Kuala Lumpur, Malaysia. With the 30-year dedication in the semiconductor...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

More news about Science and technology...


News published on and distributed by: